glp-1 ckd Real-World Evidence for Receptor Agonists Across the Spectrum – AJKD Blog GLP-1 RAs for Diabetic Kidney

Retatrutide is a next level drug because it is a triple agonist, adding metabolic benefits to those provided by other drugs

As a physician, Ive seen a growing need for a more personalized, gentler approach: microdosing

Dosing in the Phase 3 Diabetes Trial (TRANSCEND-T2D-1) A1C reduction: -1.7% to -2.0% across doses (from baseline 7-9.5%) Weight loss at 12 mg: 16.8% (-36.6 lbs) at 40 weeks Discontinuation due to adverse events was relatively low across all doses, similar to the patterns seen in TRIUMPH-4 The diabetes population typically loses less weight on GLP-1 drugs than the obesity-only population, which is consistent with what was observed: ~17% weight loss in T2D vs

I wont see my final results for roughly nine months

What Is Lipohypertrophy and Why Should You Care